Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sE-cad neutralizing antibody
- Development stage
- Preclinical
- Lead developer
- Beijing Friendship Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
sE-cad neutralizing antibody is a preclinical monoclonal antibody designed to target and neutralize soluble E-cadherin (sE-cad) fragments. In colorectal cancer (CRC), matrix stiffness promotes the palmitoylation of E-cadherin via the palmitoyltransferase ZDHHC8, leading to its proteolytic cleavage and the release of sE-cad. These soluble fragments act as immunosuppressive factors by binding to the co-inhibitory receptor KLRG1 on cytotoxic T cells, driving T-cell exhaustion. By neutralizing sE-cad, the antibody blocks its interaction with KLRG1, reversing T-cell inhibition and restoring anti-tumor immunity. Preclinical studies have demonstrated that combining sE-cad neutralizing antibody with anti-PD-1 therapy synergistically inhibits tumor growth in colorectal cancer models.
- Other names
- anti-sE-cad neutralizing antibodyanti-soluble E-cadherin neutralizing antibodysoluble E-cadherin neutralizing antibody
02
Targets
MAFA (V-maf musculoaponeurotic fibrosarcoma oncogene homolog A)sEcad (Soluble E-cadherin)CDH1 (Cadherin-1)
Beyond the preview
Go deeper on sE-cad neutralizing antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sE-cad neutralizing antibody.